Cancer is the leading cause of death across the globe. For years now, researchers have performed studies focused on how to stop this deadly disease in its tracks. Progress in understanding cancer biology and the immune system have fueled major advances. Still, three major problems represent a large unmet need in current cancer therapies, including immunotherapies:
- Drug Resistance
- Immune System Evasion
- Disease Recurrence
BioEclipse Therapeutics™ is committed to overcoming these challenges. Using our proprietary technology, we have developed a multi-modal therapeutic approach the combines supercharged immune cells known as cytokine-induced killer (CIK) cells with an adapted oncolytic virus that infects and kills malignant cells. The result of this combination is a multi-mechanistic, targeted treatment that we believe will not only defeat the cancer, but also protect patients from relapse and recurrence, through a durable immune response that prevents the development of new cancers.